Fundraising Fox
Citius Pharmaceuticals
NASDAQ: CTXRCranford, US · Nevada corporation
Find your way into Citius Pharmaceuticals
Sign up to see every warm intro you have to Citius Pharmaceuticals
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Citius Pharmaceuticals team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Citius Pharmaceuticals is a late-stage biopharmaceutical company developing and commercializing critical care products, including anti-infectives, oncology and adjunct cancer care treatments, stem cell therapy, and prescription products.
Founders & leadership
LM
Leonard MazurFounder · Chief Executive OfficerLeonard Mazur is Executive Officer and Director at Citius Pharmaceuticals, a late-stage biopharmaceutical company developing critical care products including anti-infectives, oncology treatments, and stem cell therapies.
JB
Jaime BartushakCFOJaime Bartushak is an Executive Officer at Citius Pharmaceuticals with experience in pharmaceutical operations, drug development commercialization, M&A transactions, and capital raising across public and private contexts.
MS
Myron S. CzuczmanChief Medical Officer and EVPChief Medical Officer and Executive Vice President of Citius Pharmaceuticals, a late-stage biopharmaceutical company developing critical care products. Czuczman has background in hematology, oncology, immunology, and clinical and translational research across pharmaceutical, biotech, and academic settings.
Board
CW
Carol WebbBoard director
SD
Suren DutiaBoard director
WK
William KaneBoard director
HS
Howard SafirBoard director
EH
Eugene HolukaBoard director
Reported raises · per SEC filings
Form D private placements$21.3M disclosed across 6 of 7 rounds · 2016–2026
▶$20MraisedFeb 2021 · 7 investors · PharmaceuticalsRule 506(b)
▶$20MraisedFeb 2021 · 7 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Carol WebbDirector
- Suren DutiaDirector
- Leonard MazurExecutive Officer, Director
- Myron HolubiakExecutive Officer, Director
- Eugene HolukaDirector
- Jaime BartushakExecutive Officer
- William KaneDirector
- Howard SafirDirector
- Offering amount
- $20M
- Amount sold
- $20M
- Sales commissions
- $1.4M
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Jan 2021
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$220.6KraisedMay 2020 · 5 investors · PharmaceuticalsRule 506(b)
▶$220.6KraisedMay 2020 · 5 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Eugene HolukaDirector
- Howard SafirDirector
- Suren DutiaDirector
- William KaneDirector
- Carol WebbDirector
- Jaime BartushakExecutive Officer
- Myron HolubiakExecutive Officer, Director
- Leonard MazurExecutive Officer, Director
- Offering amount
- $3.5M
- Amount sold
- $220.6K
- Sales commissions
- $15.4K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- May 2020
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$428.8KraisedApr 2019 · 3 investors · PharmaceuticalsRule 506(b)
▶$428.8KraisedApr 2019 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Carol WebbDirector
- Myron HolubiakExecutive Officer, Director
- Leonard MazurExecutive Officer, Director
- Suren DutiaDirector
- Jaime BartushakExecutive Officer
- William KaneDirector
- Howard SafirDirector
- Eugene HolukaDirector
- Offering amount
- $428.8K
- Amount sold
- $428.8K
- Sales commissions
- $30K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Apr 2019
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$83.7KraisedMay 2018 · 2 investors · PharmaceuticalsRule 506(b)
▶$83.7KraisedMay 2018 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Suren DutiaDirector
- Howard SafirDirector
- Myron HolubiakExecutive Officer, Director
- Jaime BartushakExecutive Officer
- Leonard MazurExecutive Officer, Director
- Carol WebbDirector
- Eugene HolukaDirector
- William KaneDirector
- Offering amount
- $83.7K
- Amount sold
- $83.7K
- Sales commissions
- $5.9K
- First sale
- Mar 2018
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$40KraisedDec 2017 · 8 investors · PharmaceuticalsRule 506(b)
▶$40KraisedDec 2017 · 8 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Howard SafirDirector
- Leonard MazurExecutive Officer, Director
- Myron HolubiakExecutive Officer, Director
- Suren DutiaDirector
- Eugene HolukaDirector
- Carol WebbDirector
- William KaneDirector
- Jaime BartushakExecutive Officer
- Offering amount
- $40K
- Amount sold
- $40K
- Sales commissions
- $2.8K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Dec 2017
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$549.9KraisedFeb 2017 · 9 investors · PharmaceuticalsRule 506(b)
▶$549.9KraisedFeb 2017 · 9 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- William KaneDirector
- Myron HolubiakExecutive Officer, Director
- Howard SafirDirector
- Eugene HolukaDirector
- Carol WebbDirector
- Leonard MazurExecutive Officer, Director
- Suren DutiaDirector
- Offering amount
- $6M
- Amount sold
- $549.9K
- Minimum investment
- $50K
- First sale
- Nov 2016
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$26.8Mvaluation at IPOSep 2019 · $0.90/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Related companies · 4
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
NasdaqNasdaq operates a technology infrastructure platform for financial markets across three business segments: Capital Access Platforms (which includes listing services, indices, and analytics tools), Financial Technology (comprising compliance, regulatory, and capital markets software), and Market Services (equities and derivatives trading operations). The company serves financial institutions, listed companies, investment managers, and regulatory agencies globally.
Seeking AlphaSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
PublicPublic is a trading platform that allows users to buy and sell cryptocurrencies including Bitcoin, Ethereum, and memecoins through accounts managed by Zero Hash LLC, a New York State-licensed virtual currency business.
Companies working in the same space as Citius Pharmaceuticals.
In the news
Citius Pharmaceuticals posts $7.1M LYMPHIR revenue, wider loss | CTXR Quarterly Report (10-Q)stocktitan.net · Aug 2026Frequently asked questions
- What does Citius Pharmaceuticals do?
- Citius Pharmaceuticals is a late-stage biopharmaceutical company developing and commercializing critical care products, including anti-infectives, oncology and adjunct cancer care treatments, stem cell therapy, and prescription products.
- Who founded Citius Pharmaceuticals?
- Citius Pharmaceuticals was founded by Leonard Mazur.
- How much funding has Citius Pharmaceuticals raised?
- Citius Pharmaceuticals has disclosed $21.3M raised across 6 of its 7 known rounds.
- Where is Citius Pharmaceuticals headquartered?
- Citius Pharmaceuticals is headquartered in Cranford, US.